Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790081 | 0.88 | DGAT1 (0.47) | DGAT1LOXL2PKMFFAR1JAK3 | |
| SCHEMBL16660873 | 0.83 | DGAT1 (0.44) | DGAT1LOXL2PKMFFAR1JAK3 | |
| SCHEMBL16787869 | 0.82 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL16660877 | 0.81 | DGAT1 (0.61) | DGAT1 | |
| SCHEMBL16661182 | 0.81 | DGAT1 (0.59) | DGAT1 | |
| SCHEMBL16661015 | 0.77 | DGAT1 (0.56) | DGAT1 | |
| SCHEMBL16660990 | 0.75 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL16787895 | 0.72 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL16661189 | 0.70 | DGAT1 (0.88) | DGAT1 | |
| SCHEMBL16661191 | 0.70 | DGAT1 (0.82) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885LOXL2 619/4885PKM 4064/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | DGAT1 1688/4885LOXL2 619/4885PKM 4064/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885LOXL2 619/4885PKM 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.